The CD200 gene (aka MOX-2, OX-2) is located on chromosome 3 and encodes a type-1 membrane glycoprotein. 1 This protein belongs to the immunoglobulin superfamily and is expressed on many different cell types including T and B lymphocytes and dendritic cells.
2 CD200 binds multiple membrane receptor isoforms (CD200R) which have a more tissue restricted expression. 3, 4 The best characterized isoform, CD200R1, has a longer cytoplasmic tail containing three conserved tyrosine residues that can be phosphorylated. 1 These phosphorylated residues interact with signalling adaptor molecules such as Shc, suggesting that the CD200R1 can signal upon binding CD200 ligand providing a more localized response than that provided by cytokines. 5 Although CD200 (À/À) -deficient mice appear grossly normal and live a normal lifespan, they are susceptible to tissue-specific autoimmunity, suggesting that the function of this protein is to induce immune suppression through the CD200R.
6 CD200 also appears to have an alternative role in regulating osteoclast development. 7 In leukaemia, CD200 has been shown to be upregulated in B cells from patients with chronic lymphocytic leukemia. 8 More recently, CD200 has been shown to be an independent prognostic factor for patients with multiple myeloma. 9 In this latter study, expression of CD200 was associated with a bad prognosis. Here we report that in acute myeloid leukaemia (AML), there is a correlation between CD200 expression and the presence of the core binding factor (CBF) associated abnormalities, t(8;21) and inv(16). However, at the same time CD200 expression was linked to worse overall survival in other AML subsets. These data indicate that CD200 is also of prognostic value in AML.
Using a cohort of 184 AML trial patients (all processed and diagnosed at Cardiff as part of the Medical Research Council (MRC) AML Trials), complementary RNA was prepared from each sample and hybridized to Affymetrix Human 133A oligonucleotide arrays which allowed the analysis of CD200 gene expression. In approximately 43% of AML patients, CD200 had a 'present' Affymetrix call (CD200 present ) with the remainder giving an absent call (CD200 absent ). CD200 present calls were highly correlated with abnormalities affecting CBF (24/28 vs 56/156, P ¼ 0.0001). There was no evidence of any association with age at diagnosis (mean ages: present 49 years vs absent 50 years, P ¼ 0.7), WBC (P ¼ 0.3) or sex (P ¼ 0.6), however, larger numbers of patients will be required to provide more reliable evidence and allow for adjustment of clinical and demographic parameters. Despite the association of CD200 expression with these good risk subtypes, analyses of survival stratified for CBF abnormalities showed that CD200 was significantly associated with worse survival (HR 1.68, 95% CI 1.08-2.62, P ¼ 0.02; Figure 1a and b). 
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We also examined the correlation of level of CD200 gene expression with AML subtype (Figure 1c ). As might be expected from the high frequency of CD200 present patients in t(8;21) leukaemias, these patients also significantly overexpressed CD200 by 1.8-fold when compared to FAB-M2 patients without this cytogenetic abnormality (P ¼ 0.03). Induction of CD200 may be a direct consequence of AML1-ETO expression, because human primary cells transduced with this fusion gene also overexpress CD200 (A.Tonks, submitted). Furthermore, patients expressing an inv(16) mutation (generally associated with FAB-M4) also significantly overexpressed CD200 when compared to M4 patients without an inv(16) mutation (1.3-fold; P ¼ 0.02). Additionally, Cox regression shows that, when adjusted for the type of leukaemia, the level of CD200 expression was significantly associated with worse overall survival (P ¼ 0.04). This data suggests that CD200 may have independent prognostic value in AML.
Our data analysis was consistent using all available Affymetrix probe sets (209582_s_at; 209583_s_at). CD200 expression by microarray analysis was validated by real-time RT-PCR for 20 AML patients for which corresponding messenger ribonucleic acid samples were still available (Figure 2a ). These data sets were highly correlative (r ¼ 0.763, P ¼ 0.001). We also carried out assessment of CD200 expression at the protein level by flow cytometric analysis using another set of 15 patients for which archival material was available. Cells were stained with PEconjugated anti-CD200 (clone MRCOX-104) in combination with CD45-FITC and CD34-PERCP (all from Becton Dickinson, BD, UK). Again, we found a correlation (r ¼ 0.631; P ¼ 0.01) between Affymetrix CD200 expression and protein expression (Figure 2b ). 
The mechanism by which CD200 influences survival is intriguing. The function of CD200 includes induction of immune suppression through interaction with its receptor, CD200R, [3] [4] [5] [6] suggesting a possible role for this molecule in influencing immune surveillance. In conclusion, these data show for the first time the potential role of CD200 in influencing survival in AML and its association with CBF leukaemias.
